Lexicon Pharmaceuticals to Present at the Needham Biotechnology & Medical Technology Conference
June 07 2007 - 7:30AM
PR Newswire (US)
THE WOODLANDS, Texas, June 7 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Alan J.
Main, Ph.D., Lexicon's executive vice president of pharmaceutical
research, will present at the Sixth Annual Needham Biotechnology
& Medical Technology Conference at The New York Palace Hotel in
New York City on Thursday, June 14, 2007 at 8:00 a.m. Eastern Time.
A live webcast of Lexicon's presentation may be accessed on its
corporate website at http://www.lexpharma.com/. An archived version
of the webcast will be available on the website through June 22,
2007. About Lexicon Lexicon is a biopharmaceutical company focused
on the discovery and development of breakthrough treatments for
human disease. Lexicon currently has clinical programs underway for
such areas of major unmet medical need as irritable bowel syndrome
and cognitive disorders. The company has used its proprietary gene
knockout technology to discover more than 100 promising drug
targets and create an extensive pipeline of clinical and
preclinical programs in the therapeutic areas of diabetes and
obesity, cardiovascular disease, psychiatric and neurological
disorders, cancer, immune system disorders and ophthalmic disease.
To advance the development and commercialization of its programs,
Lexicon is working both independently and through collaborators
including Bristol-Myers Squibb Company, Genentech, Inc., N.V.
Organon and Takeda Pharmaceutical Company Limited. For additional
information about Lexicon and its programs, please visit
http://www.lexpharma.com/. Safe Harbor Statement This press release
contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to
successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2006, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: Bobbie Faulkner, Manager, Investor Relations, Lexicon
Pharmaceuticals, Inc., +1-281-863-3503, Web site:
http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024